Danna Jennings1, John Seibyl2, Marwan Sabbagh2, Florence Lai2, William Hopkins2, Santi Bullich2, Monica Gimenez2, Cornelia Reininger2, Barbara Putz2, Andrew Stephens2, Ana M Catafau2, Ken Marek2. 1. From the Institute for Neurodegenerative Disorders (D.J., J.S., K.M.), New Haven, CT; Banner Sun Health Research Institute (M.S.), Sun City, AZ; McLean Hospital (F.L.), Belmont, MA; University of Vermont College of Medicine (W.H.), Burlington, VT; Piramal Imaging GmbH (S.B., A.S., A.M.C.), Berlin, Germany; MRI Research Unit (M.G.), Hospital del Mar, Barcelona, Spain; Navidea Biopharmaceuticals (C.R.) (formerly at Bayer Healthcare); and Bayer Healthcare (B.P.), Berlin, Germany. DJennings@indd.org. 2. From the Institute for Neurodegenerative Disorders (D.J., J.S., K.M.), New Haven, CT; Banner Sun Health Research Institute (M.S.), Sun City, AZ; McLean Hospital (F.L.), Belmont, MA; University of Vermont College of Medicine (W.H.), Burlington, VT; Piramal Imaging GmbH (S.B., A.S., A.M.C.), Berlin, Germany; MRI Research Unit (M.G.), Hospital del Mar, Barcelona, Spain; Navidea Biopharmaceuticals (C.R.) (formerly at Bayer Healthcare); and Bayer Healthcare (B.P.), Berlin, Germany.
Abstract
OBJECTIVE: To investigate brain β-amyloid binding in subjects with Down syndrome (DS) using [(18)F]florbetaben PET imaging. METHODS: Thirty-nine subjects with DS (46.3 ± 4.7 years) were assessed with [(18)F]florbetaben PET imaging. Three blinded independent readers assessed the scans to provide a visual analysis. The primary quantitative imaging outcome was a standardized uptake value ratio (SUVR) obtained for 6 brain regions. Cognitive status was evaluated using the Dementia Screening Questionnaire for Individuals with Intellectual Disabilities (DSQIID). RESULTS: [(18)F]Florbetaben uptake was correlated with age (p < 0.0001, R(2) = 0.39); 90% of scans in subjects with DS aged 50 years or older (SUVR = 1.62 ± 0.26), 53% in those aged 45 to 49 years (SUVR = 1.43 ± 0.16), and 7% in those aged 40 to 45 years (SUVR = 1.27 ± 0.11) were visually assessed as positive. Visual and quantitative assessments were highly related (χ(2) = 11.3823, p = 0.0007; Cohen κ = 0.58). Only 2 of 34 participants were considered to have dementia by the DSQIID. CONCLUSIONS: Brain β-amyloid binding, as measured by [(18)F]florbetaben, increases with age in DS. Subjects with DS who have no evidence of dementia demonstrate brain β-amyloid binding in vivo, suggesting that [(18)F]florbetaben PET imaging may detect β-amyloid in this at-risk population.
OBJECTIVE: To investigate brain β-amyloid binding in subjects with Down syndrome (DS) using [(18)F]florbetaben PET imaging. METHODS: Thirty-nine subjects with DS (46.3 ± 4.7 years) were assessed with [(18)F]florbetaben PET imaging. Three blinded independent readers assessed the scans to provide a visual analysis. The primary quantitative imaging outcome was a standardized uptake value ratio (SUVR) obtained for 6 brain regions. Cognitive status was evaluated using the Dementia Screening Questionnaire for Individuals with Intellectual Disabilities (DSQIID). RESULTS: [(18)F]Florbetaben uptake was correlated with age (p < 0.0001, R(2) = 0.39); 90% of scans in subjects with DS aged 50 years or older (SUVR = 1.62 ± 0.26), 53% in those aged 45 to 49 years (SUVR = 1.43 ± 0.16), and 7% in those aged 40 to 45 years (SUVR = 1.27 ± 0.11) were visually assessed as positive. Visual and quantitative assessments were highly related (χ(2) = 11.3823, p = 0.0007; Cohen κ = 0.58). Only 2 of 34 participants were considered to have dementia by the DSQIID. CONCLUSIONS: Brain β-amyloid binding, as measured by [(18)F]florbetaben, increases with age in DS. Subjects with DS who have no evidence of dementia demonstrate brain β-amyloid binding in vivo, suggesting that [(18)F]florbetaben PET imaging may detect β-amyloid in this at-risk population.
Authors: Eric E Abrahamson; Elizabeth Head; Ira T Lott; Benjamin L Handen; Elliott J Mufson; Bradley T Christian; William E Klunk; Milos D Ikonomovic Journal: Dev Neurobiol Date: 2019-08-17 Impact factor: 3.964
Authors: Sylvia E Perez; Jennifer C Miguel; Bin He; Michael Malek-Ahmadi; Eric E Abrahamson; Milos D Ikonomovic; Ira Lott; Eric Doran; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson Journal: Acta Neuropathol Date: 2019-02-07 Impact factor: 17.088
Authors: Eric Doran; David Keator; Elizabeth Head; Michael J Phelan; Ron Kim; Minodora Totoiu; Jorge R Barrio; Gary W Small; Steven G Potkin; Ira T Lott Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: Frances K Wiseman; Tamara Al-Janabi; John Hardy; Annette Karmiloff-Smith; Dean Nizetic; Victor L J Tybulewicz; Elizabeth M C Fisher; André Strydom Journal: Nat Rev Neurosci Date: 2015-08-05 Impact factor: 34.870
Authors: H Diana Rosas; Eugene Hsu; Nathaniel D Mercaldo; Florence Lai; Margaret Pulsifer; David Keator; Adam M Brickman; Julie Price; Michael Yassa; Christy Hom; Sharon J Krinsky-McHale; Wayne Silverman; Ira Lott; Nicole Schupf Journal: Alzheimers Dement (Amst) Date: 2020-11-07
Authors: Alberto Lleó; Henrik Zetterberg; Jordi Pegueroles; Thomas K Karikari; María Carmona-Iragui; Nicholas J Ashton; Victor Montal; Isabel Barroeta; Juan Lantero-Rodríguez; Laura Videla; Miren Altuna; Bessy Benejam; Susana Fernandez; Silvia Valldeneu; Diana Garzón; Alexandre Bejanin; Maria Florencia Iulita; Valle Camacho; Santiago Medrano-Martorell; Olivia Belbin; Jordi Clarimon; Sylvain Lehmann; Daniel Alcolea; Rafael Blesa; Kaj Blennow; Juan Fortea Journal: Nat Commun Date: 2021-07-14 Impact factor: 14.919